NCT03201367View on ClinicalTrials.gov

Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 1, 2014

Primary Completion Date

August 1, 2016

Study Completion Date

August 1, 2016

Conditions
Portal Vein Thrombosis
Interventions
DRUG

Rivaroxaban

Rivaroxaban 10 mg/12 hour

OTHER

symptomatic therapy for ascites, abdominal pain

All Listed Sponsors
lead

Zagazig University

OTHER_GOV

NCT03201367 - Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV | Biotech Hunter | Biotech Hunter